|
JPH04218000A
(ja)
*
|
1990-02-13 |
1992-08-07 |
Kirin Amgen Inc |
修飾ポリペプチド
|
|
ES2558842T3
(es)
|
2008-06-17 |
2016-02-09 |
Indiana University Research And Technology Corporation |
Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
|
|
JP2012512898A
(ja)
|
2008-12-19 |
2012-06-07 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
ジペプチド結合薬用剤
|
|
EP2376097A4
(en)
|
2008-12-19 |
2012-10-03 |
Univ Indiana Res & Tech Corp |
PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY
|
|
WO2010148089A1
(en)
|
2009-06-16 |
2010-12-23 |
Indiana University Research And Technology Corporation |
Gip receptor-active glucagon compounds
|
|
US20120329711A1
(en)
|
2009-12-16 |
2012-12-27 |
Nordisk A/S |
Glp-1 receptor agonist compounds with a modified n-terminus
|
|
KR20130083843A
(ko)
|
2010-06-24 |
2013-07-23 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
디펩티드 연결된 약제
|
|
US8778872B2
(en)
|
2010-06-24 |
2014-07-15 |
Indiana University Research And Technology Corporation |
Amide based glucagon superfamily peptide prodrugs
|
|
MX377589B
(es)
|
2010-12-16 |
2025-03-10 |
Novo Nordisk As |
Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
|
|
NZ612297A
(en)
|
2010-12-22 |
2015-10-30 |
Univ Indiana Res & Tech Corp |
Glucagon analogs exhibiting gip receptor activity
|
|
RU2013133803A
(ru)
|
2010-12-22 |
2015-01-27 |
Маркадиа Байотек, Инк. |
Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп
|
|
KR102002783B1
(ko)
|
2011-06-10 |
2019-07-24 |
베이징 한미 파마슈티컬 컴퍼니 리미티드 |
포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
|
|
BR112014007124A2
(pt)
|
2011-11-17 |
2017-06-13 |
Univ Indiana Res & Tech Corp |
superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
|
|
HUE064694T2
(hu)
|
2012-03-22 |
2024-04-28 |
Novo Nordisk As |
Továbbítószert tartalmazó készítmények és elõállításuk
|
|
CA2872314C
(en)
|
2012-05-03 |
2021-08-31 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
|
WO2013189988A1
(en)
|
2012-06-20 |
2013-12-27 |
Novo Nordisk A/S |
Tablet formulation comprising a peptide and a delivery agent
|
|
SI2864350T1
(en)
|
2012-06-21 |
2018-08-31 |
Indiana University Research And Technology Corporation |
GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR
|
|
HUE035803T2
(en)
|
2012-12-21 |
2018-05-28 |
Sanofi Sa |
Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
|
|
US20160058881A1
(en)
|
2013-03-15 |
2016-03-03 |
Indiana University Research And Technology Corporation |
Prodrugs with prolonged action
|
|
RS58039B1
(sr)
|
2013-05-02 |
2019-02-28 |
Novo Nordisk As |
Oralno doziranje glp-1 jedinjenja
|
|
DK3004155T3
(da)
|
2013-05-28 |
2022-01-03 |
Takeda Pharmaceuticals Co |
Peptidforbindelse
|
|
WO2015022420A1
(en)
|
2013-08-16 |
2015-02-19 |
Medimmune Limited |
Gip and glp-1 receptor dual-agonists for the treatment of diabetes
|
|
WO2015035419A1
(en)
|
2013-09-09 |
2015-03-12 |
Hoffmann-La Roche Inc. |
Dosages of gip/glp-1 co-agonist peptides for human administration
|
|
CA2929459C
(en)
|
2013-11-06 |
2022-05-03 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
GB2528436A
(en)
|
2014-07-15 |
2016-01-27 |
Lancaster Univ Business Entpr Ltd |
Treatment of neurological diseases
|
|
EP3197912B1
(en)
|
2014-09-24 |
2023-01-04 |
Indiana University Research & Technology Corporation |
Lipidated amide-based insulin prodrugs
|
|
WO2016077220A1
(en)
|
2014-11-10 |
2016-05-19 |
Mb2 Llc |
Gip/glp-1 co-agonist peptides for human administration
|
|
JP2018012644A
(ja)
|
2014-11-26 |
2018-01-25 |
武田薬品工業株式会社 |
ペプチド化合物
|
|
AR103242A1
(es)
|
2015-01-09 |
2017-04-26 |
Lilly Co Eli |
Compuestos co-agonistas de gip y glp-1
|
|
WO2016131893A1
(en)
|
2015-02-18 |
2016-08-25 |
Medimmune Limited |
Incretin fusion polypeptides
|
|
US20170112897A1
(en)
|
2015-10-23 |
2017-04-27 |
Cedars-Sinai Medical Center |
Methods for treating brain insulin resistance
|
|
EP3467106B1
(en)
|
2016-05-24 |
2025-07-09 |
Takeda Pharmaceutical Company Limited |
Peptide compound
|
|
GB201620611D0
(en)
|
2016-12-05 |
2017-01-18 |
Univ Of Lancaster |
Treatment of neurological diseases
|
|
JOP20190211A1
(ar)
|
2017-03-31 |
2019-09-15 |
Takeda Pharmaceuticals Co |
ببتيد منشط لمستقبل gip
|
|
AR114353A1
(es)
|
2018-02-02 |
2020-08-26 |
Novo Nordisk As |
Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
|
|
PE20210473A1
(es)
|
2018-05-04 |
2021-03-08 |
Novo Nordisk As |
Derivados de gip y usos de estos
|
|
AU2019309798A1
(en)
|
2018-07-23 |
2021-02-11 |
Eli Lilly And Company |
Method of using a GIP/GLP1 co-agonist for diabetes
|
|
KR20250044806A
(ko)
|
2018-07-23 |
2025-04-01 |
일라이 릴리 앤드 캄파니 |
요법을 위한 gip/glp1 공효능제 사용 방법
|
|
ES3068975T3
(en)
|
2018-07-23 |
2026-06-03 |
Lilly Co Eli |
Gip/glp1 co-agonist compounds
|
|
AU2020256648B2
(en)
|
2019-04-11 |
2026-01-15 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Multi-receptor agonist and medical use thereof
|
|
CN110642935A
(zh)
|
2019-09-25 |
2020-01-03 |
成都奥达生物科技有限公司 |
一种替瑞帕肽类似物
|
|
CN110684082B
(zh)
|
2019-10-08 |
2021-12-10 |
江苏诺泰澳赛诺生物制药股份有限公司 |
Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
|
|
AU2021312323A1
(en)
|
2020-07-22 |
2023-02-02 |
Novo Nordisk A/S |
Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
|